
Phase II Study of Seribantumab in Tumors Harboring NRG1 Fusions
20/5/2026
0:00
22:57
JCO PO author Dr. Tejas Patil at University of Colorado Cancer Center shares insights into the JCO PO article, "CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (NRG1) Fusions". Host Dr. Rafeh Naqash and Dr. Patil discuss the anti-tumor activity and safety data of seribantumab from the CRESTONE study (NCT04383210).
Altri episodi di "JCO Precision Oncology Conversations"



Non perdere nemmeno un episodio di “JCO Precision Oncology Conversations”. Iscriviti all'app gratuita GetPodcast.








